Moreover, CXCR4’s involvement in drug resistance, particularly in trastuzumab treatment, has been well documented, reinforcing its critical role in the therapeutic landscape of HER2 breast cancer [45,46]. The gene discussed is CXCR4; the disease is breast cancer.